PARP1 and breast cancer: Interestingly, this trapping mechanism seems to occur at exposures that are higher than those required for catalytic inhibition.45BRCA-mutated tumour cells appear to be especially sensitive to PARP inhibition by synthetic lethality.46 In this study, BRCA mutation leading to impaired HRR may have resulted in improved response rates in patients with ovarian and breast cancer.